Ras, PI(3)K and mTOR signalling controls tumour cell growth
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
All eukaryotic cells coordinate cell growth with the availability of nutrients in their environment. The mTOR protein kinase has emerged as a critical growth-control node, receiving stimulatory signals from Ras and phosphatidylinositol-3-OH kinase (PI(3)K) downstream from growth factors, as well as nutrient inputs in the form of amino-acid, glucose and oxygen availability. Notably, components of the Ras and PI(3)K signalling pathways are mutated in most human cancers. The preponderance of mutations in these interconnected pathways suggests that the loss of growth-control checkpoints and promotion of cell survival in nutrient-limited conditions may be an obligate event in tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“many common human cancers have mutations in phosphatidylinositol 3-kinase or upstream signaling pathways (13).”
From Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth (2008) · cites this paper as [13]
In the citing paper
“PI3K signaling may be central to linking the common genetic perturbations of cancer, such as RTK mutations and PTEN loss, with altered metabolic processes, including the “lipogenic phenotype” common to many cancers, including GBM (13, 14, 17, 20).”
From An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway (2011) · cites this paper as [20]
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 8×
“So, the PI(3)K heterodimer is recruited to the membrane to generate local pools of PtdIns(3,4,5)P3.”
BackgroundInfluentialAkt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914 · cited 1×
“AMPK inhibits mTOR at least in part by the direct phosphorylation of tuberin ( Box 3 ), and cells that lack tuberin retain activated mTORC1 under conditions of low glucose as well as hypoxi”
BackgroundRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 1×
“In addition to loss of RasGAP function, Ras activity is reported to be elevated through reduced expression of a conserved microRNA (let-7) that targets the 3′ untranslated region of H-ras, N-ras and K-ras messenger RNA”
BackgroundHigh Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · cited 1×
“PTEN catalyses removal of the D3 phosphate from PtdIns(3,4,5)P 3 (the reverse of the reaction catalysed by PI(3)K) to limit and ultimately terminate PI(3)K signalling in cell”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“The existence of the S6K-based negative-feedback loop means that prolonged rapamycin treatment will probably lead to enhanced PI(3)K–AKT activation in some tumours, as has been observed in several tumour cell lines grown in culture, and in tissues from patients in clinical trials of rapamycin analogue”
Background
Cited by
Items 101–200 of 1,006
Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines
Hollestelle, A., Elstrodt, F., Nagel, J. H. A., Kallemeijn, W. W., & Schutte, M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0263 · Cited by 320
Malakar, P., Shilo, A., Mogilevsky, A., Stein, I., Pikarsky, E., Nevo, Y., Benyamini, H., Elgavish, S., Zong, X., Prasanth, K. V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1508 · Cited by 317
“The Ras-MAPK and PI3K-mTOR pathways are deregulated in many cancers, contributing to the establishment and maintenance of the transformed phenotype (52,53).”
BackgroundVisceral obesity, metabolic syndrome, insulin resistance and cancer
Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012) · Proceedings of the Nutrition Society · doi:10.1017/s002966511100320x · Cited by 309
“Eukaryotic cells coordinate cell growth in line with the availability of nutrients in their environment((89)).”
BackgroundAKT Inhibition in Solid Tumors With AKT1 Mutations
Hyman, D. M., Smyth, L. M., Donoghue, M. T. A., Westin, S. N., Bedard, P. L., Dean, E. J., Bando, H., El-Khoueiry, A. B., Pérez-Fidalgo, J. A., Mita, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.0143 · Cited by 311
“Phosphoinositide 3-kinase (PI3K)/AKT is among the most frequently activated pathways in cancer.(1,2) Activation can occur through mutation of multiple signaling nodes including PTEN, PIK3R1, PIK3CA, AKT, and mTOR.”
BackgroundMechanism of arginine sensing by CASTOR1 upstream of mTORC1
Saxton, R. A., Chantranupong, L., Knockenhauer, K. E., Schwartz, T. U., & Sabatini, D. M. (2016) · Nature · doi:10.1038/nature19079 · Cited by 308
O'Hayre, M., Salanga, C. L., Handel, T. M., & Allen, S. J. (2008) · Biochemical Journal · doi:10.1042/bj20071493 · Cited by 297
PRAS40 and PRR5-Like Protein Are New mTOR Interactors that Regulate Apoptosis
Thedieck, K., Polak, P., Kim, M. L., Molle, K. D., Cohen, A., Jenö, P., Arrieumerlou, C., & Hall, M. N. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001217 · Cited by 296
“Akt (also known as PKB) phosphorylates and inactivates TSC2 in response to growth factors [28], whereas AMPK phosphorylates and activates TSC2 in response to low energy (high AMP) [29,30].”
BackgroundCharacterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S.-Y., Robell, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5783 · Cited by 295
Astle, M. V., Hannan, K. M., Ng, P. Y., Lee, R. S., George, A. J., Hsu, A. K., Haupt, Y., Hannan, R. D., & Pearson, R. B. (2012) · Oncogene · doi:10.1038/onc.2011.394 · Cited by 295
“AKT-dependent control of cell growth and proliferation is in large part mediated by mTORC1 regulation of ribosome biogenesis and protein translation (Shaw and Cantley, 2006; Hannan et al., 2011).”
BackgroundFOXO transcription factors in cancer development and therapy
Coomans de Brachène, A., & Demoulin, J.-B. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2112-y · Cited by 284
“Yet, this signaling pathway is often constitutively active in cancers due to gain-of-function mutations in genes encoding tyrosine kinases, RAS or PI3K itself, or due to loss-of-function mutations of PTEN, for instance (reviewed in [13]).”
BackgroundJiang, S.-H., Li, J., Dong, F.-Y., Yang, J.-Y., Liu, D.-J., Yang, X.-M., Wang, Y.-H., Yang, M.-W., Fu, X.-L., Zhang, X.-X., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.008 · Cited by 288
Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer
Hopkins, B. D., Goncalves, M. D., & Cantley, L. C. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0329-9 · Cited by 288
Self-citationTargeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway
Morgan, T., Koreckij, T., & Corey, E. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909787580999 · Cited by 283
Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer
Bruntz, R. C., Lindsley, C. W., & Brown, H. A. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009217 · Cited by 276
“Growth factors, hormones, and chemokines activate the MAPK pathway by signaling through their cognate receptors and initiating a series of signaling events that leads to activation of multiple protein kinases (Shaw and Cantley, 2006).”
BackgroundApoptosis and non-apoptotic deaths in cancer development and treatment response
de Bruin, E. C., & Medema, J. P. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.07.001 · Cited by 279
“Furthermore, human tumors often display mutations in the PI3-kinase pathway, leading to activation of mTOR and thus suppression of autophagy.(59,60) These anti-autophagic mutations altogether suggest that cells need to circumvent autophagy in order to form a tumor.”
BackgroundInsulin/TOR signaling in growth and homeostasis: A view from the fly world
Grewal, S. S. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.10.010 · Cited by 279
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors
Vaira, V., Fedele, G., Pyne, S., Fasoli, E., Zadra, G., Bailey, D., Snyder, E., Faversani, A., Coggi, G., Flavin, R., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907676107 · Cited by 267
Multivalent Small-Molecule Pan-RAS Inhibitors
Welsch, M. E., Kaplan, A., Chambers, J. M., Stokes, M. E., Bos, P. H., Zask, A., Zhang, Y., Sanchez-Martin, M., Badgley, M. A., Huang, C. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.006 · Cited by 274
“…et al., 2011; Hall et al., 2002; Huang et al., 1998; Huang et al., 1997; Karnoub and Weinberg, 2008; Malumbres and Barbacid, 2003; Pacold et al., 2000; Scheffzek et al., 1997; Shaw and Cantley, 2006; Tanaka and Rabbitts, 2010; Tsutsumi et al., 2009; Vigil et al., 2010; Walker and Olson, 2005).”
Ferreira, G. B., Vanherwegen, A.-S., Eelen, G., Gutiérrez, A. C. F., Van Lommel, L., Marchal, K., Verlinden, L., Verstuyf, A., Nogueira, T., Georgiadou, M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.013 · Cited by 275
Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions
Zarour, L. R., Anand, S., Billingsley, K. G., Bisson, W. H., Cercek, A., Clarke, M. F., Coussens, L. M., Gast, C. E., Geltzeiler, C. B., Hansen, L., et al. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.01.006 · Cited by 274
Li, M., Zhang, Z., Hill, D. L., Wang, H., & Zhang, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3066 · Cited by 274
Tammi, R. H., Kultti, A., Kosma, V.-M., Pirinen, R., Auvinen, P., & Tammi, M. I. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.005 · Cited by 272
Obesity-induced Insulin Resistance and Hyperglycemia: Etiologic Factors and Molecular Mechanisms
Martyn, J. A. J., Kaneki, M., Yasuhara, S., Warner, D. S., & Warner, M. A. (2008) · Anesthesiology · doi:10.1097/aln.0b013e3181799d45 · Cited by 265
“Insulin-like growth factor-1 can behave like insulin, producing the same beneficial effects.(13,14) Obesity-associated type 2 diabetes is evidenced by increased glucose levels in the blood, which result from elevated glucose production in the liver (gluconeogenesis and glycogenolysis) and decreased glucose uptake by m…”
BackgroundO-GlcNAcylation in Cancer Biology: Linking Metabolism and Signaling
Ferrer, C. M., Sodi, V. L., & Reginato, M. J. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.05.028 · Cited by 267
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
Delire, B., & Stärkel, P. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12441 · Cited by 275
Platz, A., Egyhazi, S., Ringborg, U., & Hansson, J. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2007.12.003 · Cited by 260
“Another Ras related activity is exerted via phospholipase C linking Ras to Protein Kinase C (PKC) activation and calcium mobilization (Denhardt, 1998; Shields et al., 2000; Downward, 2003; Martin, 2003; Shaw and Cantley, 2006) (Fig.”
BackgroundPlzf Regulates Germline Progenitor Self-Renewal by Opposing mTORC1
Hobbs, R. M., Seandel, M., Falciatori, I., Rafii, S., & Pandolfi, P. P. (2010) · Cell · doi:10.1016/j.cell.2010.06.041 · Cited by 273
Arcaro, A., & Guerreiro, A. (2007) · Current Genomics · doi:10.2174/138920207782446160 · Cited by 269
Mita, M. M., Mita, A. C., Chu, Q. S., Rowinsky, E. K., Fetterly, G. J., Goldston, M., Patnaik, A., Mathews, L., Ricart, A. D., Mays, T., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0345 · Cited by 273
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Keppler‐Noreuil, K. M., Parker, V. E. R., Darling, T. N., & Martinez‐Agosto, J. A. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31531 · Cited by 270
Therapeutic Targeting of Autophagy in Disease: Biology and Pharmacology
Cheng, Y., Ren, X., Hait, W. N., & Yang, J.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.007120 · Cited by 262
“Phosphatase and tensin homolog (PTEN), a phosphoinositide-3 phosphatase, antagonizes the signaling of the Akt/PKB pathway and is an activator of autophagy (Shaw and Cantley, 2006).”
BackgroundPhosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 254
“This region contains the binding site for GRB2 (Growth factor receptor-bound protein 2), an adapter protein that often complexes with SOS and Ras-GTPases, and facilitates KinaseHelical E545K H1047R 43% 48% ubunit (p110-α) of PI3Ks possesses a central region flanked by the N- e N-terminus of p110-α enzyme harbors the p…”
BackgroundChoo, A. Y., Kim, S. G., Vander Heiden, M. G., Mahoney, S. J., Vu, H., Yoon, S.-O., Cantley, L. C., & Blenis, J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.007 · Cited by 253
“…Mechanism for Cell Survival Under energy-limiting conditions, mTORC1 is primarily inhibited through a TSC1/2-dependent mechanism (Shaw and Cantley, 2006); mTORC1 inhibition prolongs the survival of energetically stressed cells by inhibiting the execution of cell death via…”
BackgroundInfluentialSelf-citationInjury-Induced Decline of Intrinsic Regenerative Ability Revealed by Quantitative Proteomics
Belin, S., Nawabi, H., Wang, C., Tang, S., Latremoliere, A., Warren, P., Schorle, H., Uncu, C., Woolf, C. J., He, Z., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.060 · Cited by 259
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
Platt, F. M., Hurst, C. D., Taylor, C. F., Gregory, W. M., Harnden, P., & Knowles, M. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0898 · Cited by 251
“Signaling through this pathway is commonly upregulated during tumorigenesis (2, 3).”
BackgroundNovel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer
Johnson, S. M., Gulhati, P., Rampy, B. A., Han, Y., Rychahou, P. G., Doan, H. Q., Weiss, H. L., & Evers, M. B. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2009.12.008 · Cited by 247
Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
Jiang, B.-H., & Liu, L.-Z. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.03.001 · Cited by 243
Zhao, Q. D., Viswanadhapalli, S., Williams, P., Shi, Q., Tan, C., Yi, X., Bhandari, B., & Abboud, H. E. (2015) · Circulation · doi:10.1161/circulationaha.114.011079 · Cited by 243
“mTOR is a highly conserved serine/ threonine kinase involved in vital cellular processes, including growth, gene transcription, and protein synthesis.(36) Among the best-studied properties of mTOR kinase is its involvement in protein translation and cell growth through phosphorylation of S6K and 4E-BP1.”
BackgroundA comprehensive map of the mTOR signaling network
Caron, E., Ghosh, S., Matsuoka, Y., Ashton‐Beaucage, D., Therrien, M., Lemieux, S., Perreault, C., Roux, P. P., & Kitano, H. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.108 · Cited by 241
“Inappropriate amplification of the mTOR signaling pathway, as a result of diverse genetic lesions, is implicated in a variety of human cancers (Shaw and Cantley, 2006).”
BackgroundChawla, S. P., Staddon, A. P., Baker, L. H., Schuetze, S. M., Tolcher, A. W., D'Amato, G. Z., Blay, J.-Y., Mita, M. M., Sankhala, K. K., Berk, L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6329 · Cited by 246
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
Yuan, R., Kay, A., Berg, W. J., & Lebwohl, D. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-45 · Cited by 240
Roberts, P. J., Stinchcombe, T. E., Der, C. J., & Socinski, M. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4365 · Cited by 240
“In addition to activating mutations of the Ras oncogene, this signaling node can also be activated by perturbation of components that function upstream of Ras.”
BackgroundInfluentialAKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer
Chan, J. C., Hannan, K. M., Riddell, K., Ng, P. Y., Peck, A., Lee, R. S., Hung, S., Astle, M. V., Bywater, M., Wall, M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001754 · Cited by 239
The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy
Abraham, R. T., & Gibbons, J. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2798 · Cited by 241
PTEN and PI3K/AKT in Non-Small-Cell Lung Cancer
Pérez-Ramírez, C., Cañadas-Garre, M., Molina, M. Á., Faus-Dáder, M. J., & Calleja-Hernández, M. Á. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.122 · Cited by 236
Is Cancer a Metabolic Disease?
Coller, H. A. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.07.035 · Cited by 229
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407173-5.00003-0 · Cited by 223
“In most cancers, the PI3K–Akt axis undergoes mutation in either upstream or downstream regulators (Shaw & Cantley, 2006).”
Cancer Metabolism: Current Understanding and Therapies
Counihan, J. L., Grossman, E. A., & Nomura, D. K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00775 · Cited by 226
Lin, L., Xie, F., Sun, D., Liu, J., Zhu, W., & Mao, S. (2019) · Microbiome · doi:10.1186/s40168-019-0701-y · Cited by 231
Kvitek, D. J., & Sherlock, G. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003972 · Cited by 231
“Cancer is an evolutionary process of clonal selection [43]–[45], and it is beneficial for the cells to replicate as fast as possible through the accumulation of mutations in oncogenes and tumor suppressor genes, many of which are in the homologous Ras/cAMP/PKA pathway that is recurrently mutated in our experiments [46…”
BackgroundTao, Y., Pinzi, V., Bourhis, J., & Deutsch, E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0934 · Cited by 230
“The binding of extracellular ligands to IGF1R stimulates Ras, and this initiates Raf activation”
BackgroundOxidative phosphorylation in cancer cells
Solaini, G., Sgarbi, G., & Baracca, A. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.09.003 · Cited by 231
KRAS Mutation: Should We Test for It, and Does It Matter?
Roberts, P. J., & Stinchcombe, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0454 · Cited by 228
Breuleux, M., Klopfenstein, M., Stephan, C., Doughty, C. A., Barys, L., Maira, S.-M., Kwiatkowski, D., & Lane, H. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0668 · Cited by 225
“Inhibition of mTORC1 can induce AKT S473 phosphorylation in a subset of cancer cell lines and patient tumors (9–12), an event which may attenuate tumor responses (8, 13, 14).”
Guo, D., Hildebrandt, I. J., Prins, R. M., Soto, H., Mazzotta, M. M., Dang, J., Czernin, J., Shyy, J. Y.-J., Watson, A. D., Phelps, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906606106 · Cited by 232
“Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signaling controls tumor cell growth.”
BackgroundOncogenic pathways and the electron transport chain: a dangeROS liaison
Raimondi, V., Ciccarese, F., & Ciminale, V. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0651-y · Cited by 220
Biomarkers for Colorectal Cancer
Tanaka, T., Tanaka, M., Tanaka, T., & Ishigamori, R. (2010) · International Journal of Molecular Sciences · doi:10.3390/ijms11093209 · Cited by 228
“K-ras, encoding a Ras family protein, functions as a guanine nucleotide binding protein that is involved in a signal transduction pathway including the phosphatidylinositol-3-kinase and serine/threonine protein kinase B pathways [13].”
BackgroundTargeting mTOR and Metabolism in Cancer: Lessons and Innovations
Magaway, C., Kim, E., & Jacinto, E. (2019) · Cells · doi:10.3390/cells8121584 · Cited by 225
PTEN signaling in brain: neuropathology and tumorigenesis
Endersby, R., & Baker, S. J. (2008) · Oncogene · doi:10.1038/onc.2008.239 · Cited by 222
Liu, Q., Wang, J., Kang, S. A., Thoreen, C. C., Hur, W., Ahmed, T., Sabatini, D. M., & Gray, N. S. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101520v · Cited by 219
The Proteomic Landscape of Triple-Negative Breast Cancer
Lawrence, R. T., Perez, E. M., Hernández, D., Miller, C. P., Haas, K. M., Irie, H. Y., Lee, S.-I., Blau, C. A., & Villén, J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.050 · Cited by 224
“For example, the AKT1/2 inhibitor MK-2206 was not associated with expression of AKT isoforms, but was significantly associated with expression of RPS6KB2 (R = 0.84, p = 3.54 3 10 4) (Figure 7F), which lies downstream in the signaling pathway (Shaw and Cantley, 2006).”
BackgroundInfluentialTel2 Regulates the Stability of PI3K-Related Protein Kinases
Takai, H., Wang, R. C., Takai, K. K., Yang, H., & de Lange, T. (2007) · Cell · doi:10.1016/j.cell.2007.10.052 · Cited by 217
“The PI3K-AKT- mTOR signaling pathway is frequently altered in human cancer (Shaw and Cantley, 2006; Sabatini, 2006).”
Marty, B., Maire, V., Gravier, E., Rigaill, G., Vincent-Salomon, A., Kappler, M., Lebigot, I., Djelti, F., Tourdès, A., Gestraud, P., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2204 · Cited by 216
“…lipid second messenger in tumourigenesis, in particular by activating Akt, which binds to membrane-associated PIP3 through its plekstrin homology domain, and other signalling molecules involved in a variety of cellular events, such as survival, proliferation, cell motility and invasion [26].”
The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma
Li, X., Tang, J., Huang, W., Wang, F., Li, P., Qin, C., Qin, Z., Zou, Q., Wei, J., Hua, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21726 · Cited by 222
“com/oncotarget pathway played a vital role in various cellular processes, such as cell growth, proliferation and survival [28, 29].”
BackgroundSignaling pathways in renal cell carcinoma
Banumathy, G., & Cairns, P. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.7.13247 · Cited by 221
“Alternatively, signaling proteins that are centrally located in important cancer-associated signaling networks can serve as therapeutic targets, even though their function is not specifically altered as part of the disease etiology.(15,16) This review will summarize the major signaling pathways known to be involved in…”
BackgroundModulation of Apoptosis by Natural Products for Cancer Therapy
Fulda, S. (2010) · Planta Medica · doi:10.1055/s-0030-1249961 · Cited by 211
mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome
Shackelford, D. B., Vasquez, D. S., Corbeil, J., Wu, S., Leblanc, M., Wu, C.-L., Vera, D. R., & Shaw, R. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900465106 · Cited by 205
“In addition to PJS, these diseases include Cowden’s disease, tuberous sclerosis complex, and neurofibromatosis type I, due to inactivating mutation in the PTEN, TSC1, TSC2, or NF1 genes, respectively (14).”
BackgroundSelf-citationWnt and beyond Wnt: Multiple mechanisms control the transcriptional property of β-catenin
Jin, T., George Fantus, I., & Sun, J. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.04.014 · Cited by 215
Behbakht, K., Sill, M. W., Darcy, K. M., Rubin, S. C., Mannel, R. S., Waggoner, S., Schilder, R. J., Cai, K. Q., Godwin, A. K., & Alpaugh, R. K. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.06.022 · Cited by 211
mTOR-Dependent Cell Survival Mechanisms
Hung, C.-M., Garcia-Haro, L., Sparks, C. A., & Guertin, D. A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008771 · Cited by 203
Kennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S., McBryan, T., Doyle, B., McKay, C., Oien, K. A., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.020 · Cited by 213
“This is consistent with the ability of RAS, but not BRAF, to activate AKT1 (Supplementary Figure 3b) (Shaw and Cantley, 2006), which in turn is able to antagonize SAHF formation.”
InfluentialMatsuo, T., Otsubo, Y., Urano, J., Tamanoi, F., & Yamamoto, M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01039-06 · Cited by 213
Reactive oxygen species and HIF-1 signalling in cancer
Galanis, A., Pappa, A., Giannakakis, A., Lanitis, E., Dangaj, D., & Sandaltzopoulos, R. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.028 · Cited by 208
Lin, A.-L., Zheng, W., Halloran, J. J., Burbank, R. R., Hussong, S. A., Hart, M. J., Javors, M., Shih, Y.-Y. I., Muir, E., Fonseca, R. S., et al. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.82 · Cited by 208
Endometrial carcinoma: pathology and genetics
Prat, J., Gallardo, A., Cuatrecasas, M., & Catasús, L. (2007) · Pathology · doi:10.1080/00313020601136153 · Cited by 206
“PI3Ks are key players in many intracellular signalling networks which regulate cell proliferation, growth, transformation, adhesion, survival, apoptosis, and motility.(104) Such regulation favours tumorigenesis and enhances cell proliferation and growth while apoptosis is suppressed.”
BackgroundCragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35437 · Cited by 207
Ahmad, A., Biersack, B., Li, Y., Kong, D., Bao, B., Schobert, R., Padhye, S., & Sarkar, F. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990078 · Cited by 200
“The mTOR is an important molecule downstream of Akt, and is activated when Akt abrogates the suppressive action of tumor suppressor tuberin (also known as tuberous sclerosis complex 1, TSC1) on mTOR [37,39].”
BackgroundInfluentialRegulation of mRNA Translation by Signaling Pathways
Roux, P. P., & Topisirovic, I. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012252 · Cited by 194
Tumor Suppression and Promotion by Autophagy
Ávalos, Y., Canales, J., Bravo-Sagua, R., Criollo, A., Lavandero, S., & Quest, A. F. G. (2014) · BioMed Research International · doi:10.1155/2014/603980 · Cited by 196
“PI3K Upstream inhibitors of autophagy via AKT1 activation Gain-of-function mutations in many cancer types [36, 38]”
The role of autophagy in tumour development and cancer therapy
Rosenfeldt, M. T., & Ryan, K. M. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001306 · Cited by 196
Glucose metabolism in cancer cells
Annibaldi, A., & Widmann, C. (2010) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32833a5577 · Cited by 196
Radiation-induced signaling pathways that promote cancer cell survival (Review)
HEIN, A. L., OUELLETTE, M. M., & YAN, Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2614 · Cited by 201
Araki, K., & Miyoshi, Y. (2018) · Breast Cancer · doi:10.1007/s12282-017-0812-x · Cited by 196
Soond, D. R., Bjørgo, E., Moltu, K., Dale, V. Q., Patton, D. T., Torgersen, K. M., Galleway, F., Twomey, B., Clark, J., Gaston, J. S. H., et al. (2010) · Blood · doi:10.1182/blood-2009-07-232330 · Cited by 195
Barbareschi, M., Buttitta, F., Felicioni, L., Cotrupi, S., Barassi, F., Del Grammastro, M., Ferro, A., Dalla Palma, P., Galligioni, E., & Marchetti, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0266 · Cited by 193
“derangements could be candidate targets for cancer therapy (1, 3, 4).”
BackgroundInfluentialGrundmann, S., Hans, F. P., Kinniry, S., Heinke, J., Helbing, T., Bluhm, F., Sluijter, J. P. G., Hoefer, I., Pasterkamp, G., Bode, C., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.000323 · Cited by 198
Lipidomics at the Interface of Structure and Function in Systems Biology
Gross, R. W., & Han, X. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.01.014 · Cited by 191
“…(e.g., eicosanoids, lysolipids, phosphoinositides, endocannabinoids) that reside in biologic membranes in a latent state which can be activated either by hydrolysis and/or covalent transformation (e.g., Wolf and Gross 1985; Shaw and Cantley, 2006; Chiang et al., 2006; Simon and Cravatt, 2006).”
BackgroundHung, K. E., Maricevich, M. A., Richard, L. G., Chen, W. Y., Richardson, M. P., Kunin, A., Bronson, R. T., Mahmood, U., & Kucherlapati, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908682107 · Cited by 198
“The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that integrates multiple signals to regulate cell growth and proliferation through control of mRNA translation, ribosome synthesis, autophagy, and metabolism (27).”
BackgroundOgino, A., Kitao, H., Hirano, S., Uchida, A., Ishiai, M., Kozuki, T., Takigawa, N., Takata, M., Kiura, K., & Tanimoto, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0681 · Cited by 194
“Next, we analyzed the interaction between ErbB3 and p85a, which is the regulatory subunit of type 1a PI3K (40).”
BackgroundMethodInfluentialDetection and isolation of circulating tumor cells: Principles and methods
Esmaeilsabzali, H., Beischlag, T. V., Cox, M. E., Parameswaran, A. M., & Park, E. J. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.08.016 · Cited by 189
Answering the ultimate question “What is the Proximal Cause of Aging?”
Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100525 · Cited by 190
“Activation of the PI3K/mTOR pathway is the most common alteration (and therapeutic target) in cancer [215-227].”
BackgroundArchitecture of the human GATOR1 and GATOR1–Rag GTPases complexes
Shen, K., Huang, R. K., Brignole, E. J., Condon, K. J., Valenstein, M. L., Chantranupong, L., Bomaliyamu, A., Choe, A., Hong, C., Yu, Z., et al. (2018) · Nature · doi:10.1038/nature26158 · Cited by 192
Fan, Q.-W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., & Weiss, W. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2154 · Cited by 192
Romero, Y., Bueno, M., Ramirez, R., Álvarez, D., Sembrat, J. C., Goncharova, E. A., Rojas, M., Selman, M., Mora, A. L., & Pardo, A. (2016) · Aging Cell · doi:10.1111/acel.12514 · Cited by 188
“For example, AKT, which is involved in activation of mTOR, and BCL2L1 that sequesters beclin 1, are overexpressed in old fibroblasts with a negative regulation of autophagy (Shaw & Cantley, 2006; Maiuri et al., 2007).”
BackgroundLópez-Lago, M. A., Okada, T., Murillo, M. M., Socci, N., & Giancotti, F. G. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01578-08 · Cited by 184
“Interestingly, several other phakomatoses are caused by heterozygous mutations in tumor suppressor genes (NF1 for type 1 neurofibromatosis, PTEN for Cowden disease, LKB1 for Peutz-Jeghers syndrome, and TSC1 and TSC2 for tuberous scleroses 1 and 2) that negatively regulate mTORC1 signaling.”
BackgroundInfluentialVIEDMA-RODRÍGUEZ, R., BAIZA-GUTMAN, L., SALAMANCA-GÓMEZ, F., DIAZ-ZARAGOZA, M., MARTÍNEZ-HERNÁNDEZ, G., ESPARZA-GARRIDO, R. R., VELÁZQUEZ-FLORES, M. A., & ARENAS-ARANDA, D. (2014) · Oncology Reports · doi:10.3892/or.2014.3190 · Cited by 182
“Moreover, several tumors are characterized by activating mutations of the key signal transducers connecting RTK to mTOR, including the small GTPase Ras, phosphatidylinositol 3-kinase (PI3K), as well as the Akt1 kinases and 3-phosphoinositide dependent protein kinase 1 (PDPK1) (132,133).”
BackgroundThe Hallmarks of Flavonoids in Cancer
Ponte, L. G. S., Pavan, I. C. B., Mancini, M. C. S., da Silva, L. G. S., Morelli, A. P., Severino, M. B., Bezerra, R. M. N., & Simabuco, F. M. (2021) · Molecules · doi:10.3390/molecules26072029 · Cited by 180
Modeling cancer metabolism on a genome scale
Yizhak, K., Chaneton, B., Gottlieb, E., & Ruppin, E. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145307 · Cited by 183
“The metabolic switch promoting deregulated growth is often triggered by mutations in signaling pathways that rest at the crux of anabolic and energetic homeostasis, such as HIF-1 a , PI3K/AKT, mTOR and AMPK (Shaw & Cantley, 2006; Guertin & Sabatini, 2007; Wise et al , 2008; Semenza, 2010).”
BackgroundPrimary Cilia‐Mediated Mechanotransduction in Human Mesenchymal Stem Cells
Hoey, D. A., Tormey, S., Ramcharan, S., O'Brien, F. J., & Jacobs, C. R. (2012) · STEM CELLS · doi:10.1002/stem.1235 · Cited by 181
Metadata
- Authors
- Shaw, R. J., & Cantley, L. C.
- Affiliations
- Salk Institute for Biological Studies (US)
- Beth Israel Deaconess Medical Center (US)
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 424-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2144323242
- Cited by
- 2,019
- References
- 86
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 48 · 2023: 68 · 2022: 68 · 2021: 77 · 2020: 91 · 2019: 74 · 2018: 95 · 2017: 99 · 2016: 109 · 2015: 146 · 2014: 119 · 2013: 153 · 2012: 143
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM041890)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- Ras signaling, PI3K signaling, mTOR signaling, tumour cell growth, nutrient sensing, amino acids, glucose, oxygen availability, cancer mutations, carcinogenesis, cell survival
- MeSH terms
- Animals, Humans, Neoplasms, Protein Kinases, Signal Transduction, ras Proteins, Phosphatidylinositol 3-Kinases, Cell Growth Processes, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.